Business Context and Reporting Period
This Form 8-K, filed on February 19, 2026, by Bio-Rad Laboratories, Inc. (Bio-Rad), serves as a Regulation FD disclosure. It provides an update regarding Bio-Rad's investment in Sartorius AG, referencing Sartorius's financial results for the year ended December 31, 2025, which were publicly disclosed by Sartorius on February 16, 2026.
Key Financial Metrics of Sartorius AG
The filing summarizes Sartorius AG's financial data for the year ended December 31, 2025, in millions of Euros (€). Bio-Rad does not assume responsibility for the accuracy of this third-party data.
| Metric | Value (€ Millions) |
|---|---|
| Sales Revenue | 3,538.1 |
| Gross Profit | 1,636.7 |
| EBIT | 542.6 |
| Net Profit | 230.4 |
| Operating Cash Flow | 837.0 |
| Investing Cash Flow | (513.7) |
| Financing Cash Flow | (591.4) |
| Total Assets (Current + Non-current) | 9,717.3 |
| Total Liabilities (Current + Non-current) | 5,850.0 |
| Equity | 3,867.2 |
Material Changes and Prior Period Comparison
The filing text does not provide a clear value for prior period financial data or specific percentage changes versus the prior comparable period. It only presents the absolute figures for the year ended December 31, 2025.
Guidance, Outlook, and Risks
This report contains no forward-looking guidance, management commentary on future outlook, or specific risk factors related to Bio-Rad's operations. The primary disclosure is a reference to Sartorius AG's annual report for further details. Bio-Rad explicitly disclaims any liability for errors or omissions in the information publicly disclosed by Sartorius.
Investor Verification Checklist
- Verify the full text of Sartorius AG's 2025 Annual Report via the provided investor relations link for detailed segment data and risk factors.
- Confirm the current exchange rate between the Euro (€) and the US Dollar ($) to assess the impact on Bio-Rad's consolidated financials.
- Review Bio-Rad's Form 10-K for the year ended December 31, 2025, to understand the accounting treatment and valuation of the Sartorius investment.
- Assess the significance of Sartorius's negative investing and financing cash flows relative to its operating cash flow.